The Centre for the Commercialization of Antibodies and Biologics (CCAB) provides expertise in product and business development to rapidly translate inventions toward achieving a real impact within the healthcare system and the broader scientific research community.
Combining in-house capacities in the development of therapeutics, diagnostics and reagents, with the support of start-up companies in these areas, CCAB aims to:
- Help create new companies to build and sustain Canada’s economic footprint in the life sciences and biotechnology sector;
- Stimulate an increase in domestic and international partnerships and investments in Canada’s life sciences and biotechnology sector; and
- Develop novel diagnostics and therapeutics that will improve the lives of patients, within Canada and around the world.
Our Mission – to lead Canada towards establishing a major presence in the therapeutics sector.
In the past decade, recombinant antibody technology has undergone dramatic advances and now represents a major driving force in the development of new targeted therapies against cancer and other devastating diseases.
CCAB was established at the University of Toronto with the goal of creating a powerful pipeline from academic biologics discoveries to commercialization. Expanding this mission, CCAB is focused on bridging the gap in the development of Canadian therapeutics by working with founders and start-up companies developing their own technology.
To this end, CCAB provides:
C-Lab Services & Solutions
High quality antibody and protein
production and custom solutions
Business Development
Access to antibodies available for
licensing and co-development
Antibody Reagents
Research-grade antibodies
for reagent use